<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Washaya T</submitter><funding>FIC NIH HHS</funding><funding>NIH HHS</funding><pagination>1348</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12567580</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(10)</volume><pubmed_abstract>The HIV-1 epidemic continues to challenge global public health, especially in sub-Saharan Africa. The rise in drug-resistant viruses, particularly pan-resistant strains, threatens treatment effectiveness, hindering progress toward UNAIDS viral suppression goals. This is critical in low-to-middle income countries (LMICs) like Zimbabwe, where treatment options and access to drug resistance testing are limited. This cross-sectional study analyzed 102 genotypes from patients with HIV-1 RNA ≥ 1000 copies/mL after at least 6 months on a dolutegravir (DTG)-based ART. HIV-1 genotyping and drug resistance interpretation were performed using the Stanford HIV Drug Resistance Database. Overall, 62% of genotypes harbored at least one drug resistance mutation, with 27% showing integrase strand transfer </pubmed_abstract><journal>Viruses</journal><pubmed_title>Pan-Resistant HIV-1 Drug Resistance Among Highly Treated Patients with Virological Failure on Dolutegravir-Based Antiretroviral Therapy in Zimbabwe.</pubmed_title><pmcid>PMC12567580</pmcid><funding_grant_id>D43 TW011326</funding_grant_id><funding_grant_id>1D43TW011326-05</funding_grant_id><pubmed_authors>Chin'ombe N</pubmed_authors><pubmed_authors>Bote S</pubmed_authors><pubmed_authors>Mayini J</pubmed_authors><pubmed_authors>Munyati S</pubmed_authors><pubmed_authors>Manasa J</pubmed_authors><pubmed_authors>Washaya T</pubmed_authors><pubmed_authors>Chimukangara B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pan-Resistant HIV-1 Drug Resistance Among Highly Treated Patients with Virological Failure on Dolutegravir-Based Antiretroviral Therapy in Zimbabwe.</name><description>The HIV-1 epidemic continues to challenge global public health, especially in sub-Saharan Africa. The rise in drug-resistant viruses, particularly pan-resistant strains, threatens treatment effectiveness, hindering progress toward UNAIDS viral suppression goals. This is critical in low-to-middle income countries (LMICs) like Zimbabwe, where treatment options and access to drug resistance testing are limited. This cross-sectional study analyzed 102 genotypes from patients with HIV-1 RNA ≥ 1000 copies/mL after at least 6 months on a dolutegravir (DTG)-based ART. HIV-1 genotyping and drug resistance interpretation were performed using the Stanford HIV Drug Resistance Database. Overall, 62% of genotypes harbored at least one drug resistance mutation, with 27% showing integrase strand transfer </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-05-15T03:16:26.937Z</modification><creation>2026-05-15T03:12:05.179Z</creation></dates><accession>S-EPMC12567580</accession><cross_references><pubmed>41157619</pubmed><doi>10.3390/v17101348</doi></cross_references></HashMap>